Σημειώσεις επεισοδίου
Drs. Ghafourian and Kittleson consider a practical, patient-centered approach to treating ATTR-CM using stabilizers and silencers, noting that no single drug is clearly superior and that choosing one appropriate disease‑modifying therapy is crucial for eligible patients. They explain that therapy should be tailored to disease stage, phenotype, comorbidities, cost, access, and patient preference, while avoiding routine combination therapy. For advanced or progressing disease, they stress addressing reversible factors and referring to specialized centers, with future promise from amyloid‑depleting antibodies.
Ιστότοπος: c.pvroundup.com

